USA has 700K patients with 10K USD treatment cost, across world 6 million patients annually for WCK5222. Patent for 20 years.
Out licensing, Royalty, direct sale for 20 years, heavy moat in place. One drug will be launched shortly in India replacing azithromycin in severe resistant cases.
WCK4777 fast tracked. How knows Wockhardt get CDMO shares as well.
| Subscribe To Our Free Newsletter |
